Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008476
Chunk: 110

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 110
---
                                                               |
| ● | 729,246                                                                                                                            
 shares of common stock issued for the exercise of pre-funded warrants.                                                             |
| ● | 115,716                                                                                                                            
 shares of common stock issued for the reverse stock split fractional share round up.                                               |

During the year ended December 31, 2023, the Company issued:

| ● | 297,625                                                                                                                                 
 shares of common stock to settle $1.9 million of principal and $0.3 million of interest on a Convertible Note and incurred $0.5 million 
 of loss on settlement.                                                                                                                  |
| ● | 10,650                                                                                                                                  
 shares of common stock issued for vesting of restricted stock units.                                                                    |

October 2024Equity Financing

In July 2024, the Company entered into an agreement with A.G.P./Alliance Global Partners (“AGP”), as the exclusive underwriter, placement agent, or advisor in a public or private offering of up to $10,000,000 of the Company’s securities. Under the agreement, AGP was paid a $50,000 retainer fee.

On October 31, 2024, AGP served as lead underwriter along with Boustead as co-underwriter for the Company to consummate a public offering (the “Public Offering”) of an aggregate of (i) 395,574 shares of common stock (the “Common Stock”) and 2,555,246 pre-funded warrants to purchase up to 2,555,246 shares of common stock (the “Pre-Funded Warrants”), and (ii) 2,950,820 common stock purchase warrants to purchase up to 2,950,820 shares of common stock (the “Common Warrants”). Each share of common stock, or a pre-funded warrant in lieu thereof, was sold together with an accompanying warrant to purchase one share of common stock.

The public offering price for each share of Common Stock and one accompanying Common Warrant was $1.525. The public offering price of each Pre-Funded Warrant and one accompanying Common Warrant was $1.524, which equals the price at which one share of Common Stock and accompanying Common Warrant was sold to the public in this offering, minus $0.001. The exercise price of each Pre-Funded Warrant is $0.001 per share, until exercised. Each Common Warrant offered in the offering is exercisable for one share of Common Stock and has an initial exercise price equal to $1.40